Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data

References

• Philip A, Odabasi Z, Rodriguez J, Paetznick VL, Chen E, Rex JH, et al. In vitro synergy testing of Anidulafungin with Itraconazole, Voriconazole, and Amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother. 2005;49(8):3572–4.
   PubMed Web of Science ®Google Scholar
• Lewis RE, Kontoyiannis DP. Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro. J Antimicrob Chemother. 2005;56(5):887–92.
   PubMed Web of Science ®Google Scholar
• Heyn K, Tredup A, Salvenmoser S, Müller FM. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother. 2005;49(12):5157–9.
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy EM, Meletiadis J, Stergiopoulou T, Demchok JP, Walsh TJ. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother. 2006;58(6):1168–76.
   PubMed Web of Science ®Google Scholar
• Perkhofer S, Lugger H, Dierich MP, Lass-Flörl C. Posaconazole enhances the activity of Amphotericin B against Aspergillus hyphae in vitro. Antimicrob Agents Chemother. 2007;51(2):791–3.
   PubMed Web of Science ®Google Scholar
• Perkhofer S, Jost D, Dierich MP, Lass-Flörl C. Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. Antimicrob Agents Chemother. 2008;52(5):1873–5.
   PubMed Web of Science ®Google Scholar
• Córdoba S, Rodero L, Vivot W, Abrantes R, Davel G, Vitale RG. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents. 2008;31(2):171–4.
   PubMed Web of Science ®Google Scholar
• Spreghini E, Orlando F, Santinelli A, Pisa E, Loretelli C, Manso E, et al. Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. Antimicrob Agents Chemother. 2009;53(9):4035–9.
   PubMed Web of Science ®Google Scholar
• Drogari-Apiranthitou M, Mantopoulou FD, Skiada A, Kanioura L, Grammatikou M, Vrioni G, et al. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. J Antimicrob Chemother. 2012;67(8):1937–40.
   PubMed Web of Science ®Google Scholar
• Planche V, Ducroz S, Alanio A, Bougnoux ME, Lortholary O, Dannaoui E. In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp. Antimicrob Agents Chemother. 2012;56(8):4500–3.
   PubMed Web of Science ®Google Scholar
• Krishnan-Natesan S, Wu W, Chandrasekar PH. In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus. Diagn Microbiol Infect Dis. 2012;73(2):135–7.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Fu Y, Edwards JE, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005;49:830–2.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WB, Coco BJ, Patterson TF. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive Aspergillosis. Antimicrob Agents Chemother. 2006;50:1567–9.
   PubMed Web of Science ®Google Scholar
• Rodríguez MM, Calvo E, Serena C, Mariné M, Pastor FJ, Guarro J. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother. 2009;53(5):2153–5.
   PubMed Web of Science ®Google Scholar
• Ruíz-Cendoya M, Mariné M, Rodríguez MM, Guarro J. Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum. Antimicrob Agents Chemother. 2009;53(4):1705–8.
   PubMed Web of Science ®Google Scholar
• Ruíz-Cendoya M, Pastor FJ, Capilla J, Guarro J. Treatment of murine Fusarium verticillioides infection with liposomal amphotericin B plus terbinafine. Int J Antimicrob Agents. 2011;37(1):58–61.
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Gebremariam T, Luo G, Fu Y, French SW, Edwards JE, et al. Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins. Antimicrob Agents Chemother. 2011;55(4):1768–70.
   PubMed Web of Science ®Google Scholar
• Takazono T, Izumikawa K, Mihara T, Kosai K, Saijo T, Imamura Y, et al. Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2009;53(8):3508–10.
   PubMed Web of Science ®Google Scholar
• Maertens A, Glasmacher R, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer. 2007;107:2888–97.
   Web of Science ®Google Scholar
• Caillot D, Thiébaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (combistrat trial). Cancer. 2007;110:2740–6.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary orsalvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98:292–9.
   PubMed Web of Science ®Google Scholar
• Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003;97:1025–32.
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:797–802.
   PubMed Web of Science ®Google Scholar
• Rojas R, Molina Josè R, Jarque I, Montes C, Serrano J, Sanz J, et al. Outcome of antifungal combination therapy for invasive mold infections in hematological patients is independent of the chosen combination. Med J Hem Infect Dis. 2012;4(1):e2012011.
   PubMedGoogle Scholar
• Candoni A, Caira M, Cesaro S, Busca A, Giacchino M, Fanci R, et al. Survey of antifungal combination therapy for treatment of proven or probable invasive fungal diseases in Italian haematological centres. The Seifem-Combo Study. Mycoses. 2014;57(6):342–50.
   PubMed Web of Science ®Google Scholar
• Lellek H, Waldenmaier D, Dahlke J, Ayuk FA, Wolschke C, Kröger N, et al. Caspofungin plus Posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients. Mycoses. 2011;54(Suppl 1):39–44.
   PubMed Web of Science ®Google Scholar
• Rieger CT, Ostermann H, Kolb HJ, Fiegl M, Huppmann S, Morgenstern N, et al. A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in hematological cancer patients. Ann Hematol. 2008;87(11):915–22.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Ratanatharathorn V, Young JA, Young JA, Raymond J, Laverdière M, et al. Micafungin alone or in combination with other systemic antifungal therapies in HSCT recipients with invasive aspergillosis. Transpl Infect Dis. 2009;11:89–93.
   PubMed Web of Science ®Google Scholar
• Mihu CN, Kassis C, Ramos ER, Jiang Y, Hachem RY, Raad II. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? Cancer. 2010;116(22):5290–6.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Boktour M, Hanna H, Torres HA, Hachem R, Raad II. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer. 2005;103:2334–7.
   PubMed Web of Science ®Google Scholar
• Marr KA, Schlamm H, Rottinghaus ST, et al. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. Abstract LB 2812, 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2012, London.
   Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60.
   PubMed Web of Science ®Google Scholar
• Böhme A, Ruhnke M, Buchheidt D, Cornely OA, Einsele H, Enzensberger R, et al. Treatment of invasive fungal infections in cancer patients-recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2009;88(2):97–110.
   PubMed Web of Science ®Google Scholar
• Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frêre P, et al. Third European Conference on Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transpl. 2011;46(5):709–18.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Andes D, Perez M, Anglim A, Bonilla H, Mathisen GE, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother. 2009;53(7):3122–5.
   PubMed Web of Science ®Google Scholar
• Reed C, Bryant R, Ibrahim AS, Edwards J Jr, Filler SG, Goldberg R, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47(3):364–71.
   PubMed Web of Science ®Google Scholar
• Reed C, Ibrahim A, Edwards JE Jr., Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother. 2006;50(11):3968–9.
   PubMed Web of Science ®Google Scholar
• Soummer A, Mathonnet A, Scatton O, Massault PP, Paugam A, Lemiale V, et al. Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis. Antimicrob Agents Chemother. 2008;52(4):1585–6.
   PubMed Web of Science ®Google Scholar
• Busca A, Marmont F, Locatelli F, Limerutti G, Sorrentino MT, Barbui A, et al. Combined antifungal therapy, iron chelation and surgical resection as treatment of hepatic zygomycosis in a patient with haematological malignancy. Mycoses. 2010;53(3):275–8.
   PubMed Web of Science ®Google Scholar
• Pagano L, Cornely OA, Busca A, Caira M, Cesaro S, Gasbarrino C, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematological diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98(10):e127–30.
   PubMed Web of Science ®Google Scholar
• Van Burik JH, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42:e61.
   PubMed Web of Science ®Google Scholar
• Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, et al. A global analysis of mucormycosis: The RetroZygo study (2005–2007). Clin Infect Dis. 2012;54(S1):S35.
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Birtel A, Vehreschild MJ, Liss B, Farowski F, Kochanek M, et al. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol. 2013;39(3):310–24.
   PubMed Web of Science ®Google Scholar
• Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int. 1994;45(3):667–71.
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117(9):2649–57.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;54(Suppl 1):73–8.
   Google Scholar
• Lukács G, Papp T, Nyilasi I, Nagy E, Vágvölgyi C. Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin. J Clin Microbiol. 2004;42(11):5400–2.
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother. 2006;50(1):96–103.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(3):5–26.
   PubMed Web of Science ®Google Scholar
• Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, et al. European conference on infections in leukemia. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European conference on infections in leukemia (ECIL 3). Haematologica. 2013;98(4):492–504.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Ibrahim A, Rolides E, Lewis RE, Lortholary O, Petrikkos G, et al. Combination therapy for mucormycosis: why, what and how? Clin Infect Dis. 2012;4(S1):S73.
   Web of Science ®Google Scholar
• Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect. 2004;10(Suppl 1):67–75.
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza C, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003;98(2):315–9.
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003;41:3623–6.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu AL, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54(10):4446–50.
   PubMed Web of Science ®Google Scholar
• Stanzani M, Tumietto F, Vianelli N, Baccarani M. Update on the treatment of disseminated fusariosis: focus on voriconazole. Ther Clin Risk Manage. 2007;3(6):1165–73.
   PubMedGoogle Scholar
• Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009. J Infect. 2010;60(5):331–7.
   PubMed Web of Science ®Google Scholar
• Liu JY, Chen WT, Ko BS, Yao M, Hsueh PR, Hsiao CH, et al. Combination antifungal therapy for disseminated fusariosis in immunocompromised patients: a case report and literature review. Med Mycol. 2011;49(8):872–8.
   PubMed Web of Science ®Google Scholar
• Cesaro S, Giacchino M, Locatelli F, Spiller M, Buldini B, Castellini C, et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis. 2007;18:7–28.
   Google Scholar
• Burgos A, Zaoutis TE, Dvorak CC, Hoffman JA, Knapp KM, Nania JJ, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008;121:1286–94.
   PubMed Web of Science ®Google Scholar
• Yilmaz D, Balkan C, Ay Y, Akin M, Karapinar B, Kavakli K. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections. Mycoses. 2011;54:234–42.
   PubMed Web of Science ®Google Scholar
• Cesaro S, Toffolutti T, Messina C, Calore E, Alaggio R, Cusinato R, et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol. 2004;73:50–5.
   PubMed Web of Science ®Google Scholar
• Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53(5):337–49.
   PubMed Web of Science ®Google Scholar
• Alioglu B, Avci Z, Canan O, Ozcay F, Demirhan B, Ozbek N. Invasive esophageal aspergillosis associated with acute myelogenous leukemia: successful therapy with combination caspofungin and liposomal amphotericin B. Pediatr Hematol Oncol. 2007;24:63–8.
   PubMed Web of Science ®Google Scholar
• Kriván G, Sinkó J, Nagy IZ, Goda V, Reményi P, Bátai A, et al. Successful combined antifungal salvage therapy with liposomal amphothericin B and caspofungin for invasive Aspergillus flavus infection in a child following allogeneic bone marrow transplantation. Acta Biomed. 2006;77(Suppl 2):17–21.
   PubMedGoogle Scholar
• Pancham S, Hemmaway C, New H, Albert E, Dokal I, Roberts IA, et al. Caspofungin for invasive fungal infections: combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation. Pediatr Transplant. 2005;9:254–7.
   PubMed Web of Science ®Google Scholar
• Schuster F, Moelter C, Schmid I, Graubner UB, Kammer B, Belohradsky BH, et al. Successful antifungal combination therapy with voriconazole and caspofungin. Pediatr Blood Cancer. 2005;15(44):682–5.
   Web of Science ®Google Scholar
• Zwitserloot AM, Warris A, van't Hek LG, van Die LE, Verweij PE, Mavinkurve-Groothuis AM. Disseminated aspergillosis in an adolescent with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;51:423–6.
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics. 2006;117:711–6.
   PubMed Web of Science ®Google Scholar
• Athanssiodou F, Tragiannidis A, Kourti M, Papageorgiou T, Velegraki A, Kalogera A. Treatment of disseminated aspergillosis with voriconazole/liposomal amphotericn B in a child with leukemia. Pediatr Blood Cancer. 2005;45:1003–4.
   PubMed Web of Science ®Google Scholar
• Dinser R, Grgic A, Kim YJ, Pfreundschuh M, Schubert J. Successful treatment of disseminated aspergillosis with the combination of voriconazole, caspofungin, granulocyte transfusions, and surgery followed by allogeneic blood stem cell transplantation in a patient with primary graft failure of an autologous stem cell graft. Eur J Haematol. 2005;74:438–41.
   PubMed Web of Science ®Google Scholar
• Elannjikal Z, Sorensen J, Schmidt H, Dupuis W, Tintelnot K, Jautzke G, et al. Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis. Ped Infect Dis. 2003;22:653–6.
   Google Scholar
• Cesaro S, Pillon M, Calore E, Alaggio R, Gamba P, Bergamo S, et al. Combination antifungal therapy and surgery for the treatment of invasive aspergillosis after hematopoietic stem cell transplantation. Pediatr Reports. 2011;3:e18.
   PubMedGoogle Scholar
• Vagace JM, Sanz-Rodriguez C, Casado MS, Alonso N, Garcia-Dominguez M, de la Llana FG, et al. Resolution of disseminated fusariosis in a child with acute leukemia treated with combined antifungal therapy: a case report. BMC Infect Dis. 2007;7:40.
   PubMed Web of Science ®Google Scholar
• Guarro J, Kantarcioglu AS, Horre R, Rodriguez-Tudela JL, Cuenca Estrella M, Berenguer J, et al. Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol. 2006;44:295–327.
   PubMed Web of Science ®Google Scholar
• Guarro J, Gams W, Pujol I, Genè J. Acremonium species: new emerging fungal opportunists – In vitro antifungal susceptibilities and review. Clin Infect Dis. 1997;25:1222–9.
   PubMed Web of Science ®Google Scholar
• Caira M, Girmenia C, Valentini CG, Sanguinetti M, Bonini A, Rossi G, et al. Scedosporiosis in patients with acute leukemia: a retrospective multicenter report. Haematologica. 2008;93(1):104–10.
   PubMed Web of Science ®Google Scholar
• Beier F, Kittan N, Holzmann T, Schardt K, Andreesen R, Holler E, et al. Successful treatment of Scedosporium apiospermum soft tissue abscess with caspofungin and voriconazole in a severely immunocompromised patient with acute myeloid leukemia. Transpl Infect Dis. 2010;12(6):538–42.
   PubMed Web of Science ®Google Scholar
• Ochiai N, Shimazaki C, Uchida R, Fuchida S, Okano A, Ashihara E, et al. Disseminated infection due to Scedosporium apiospermum in a patient with acute myelogenous leukemia. Leuk Lymphoma. 2003;44(2):369–72.
   PubMed Web of Science ®Google Scholar
• Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis. 2003;22(2):111–3.
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Grigg A, Slavin MA. Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis. Mycopathologia. 2008;166(2):83–6.
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Gomez-Lopez A, Buitrago MJ, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. Antimicrob Agents Chemother. 2006;50:2248–50.
   PubMed Web of Science ®Google Scholar
• Yang Q, Wei J, Chen Z. Fatal bronchial invasion of Scopulariopsis brevicaulis in an acute monocytic leukemia patient. Diagn Microbiol Infect Dis. 2012;73(4):369–71.
   PubMed Web of Science ®Google Scholar
• Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol. 1998;109:45–54.
   PubMed Web of Science ®Google Scholar
• Chang YH, Huang LM, Hsueh PR, Hsiao CH, Peng SF, Yang RS, et al. Acremonium pyomyositis in a pediatric patient with acute leukemia. Pediatr Blood Cancer. 2005;44:521–4.
   PubMed Web of Science ®Google Scholar
• Mattei D, Mordini N, Lo Nigro C, Gallamini A, Osenda M, Pugno F, et al. Successful treatment of Acremonium fungemia with voriconazole. Mycoses. 2005;46:511–4.
   Web of Science ®Google Scholar
• Yalaz M, Hilmioglu S, Metin D, Akisu M, Nart D, Cetin H, et al. Fatal disseminated Acremonium strictum infection in a preterm newborn: a very rare cause of neonatal septicaemia. J Med Microbiol. 2003;52:835–7.
   PubMed Web of Science ®Google Scholar
• Foell JL, Fischer M, Seibold M, Borneff-Lipp M, Wawer A, Horneff G, et al. Lethal double infection with Acremonium strictum and Aspergillus fumigatus during induction chemotherapy in a child with ALL. Pediatr Blood Cancer. 2007;49(6):858–61.
   PubMed Web of Science ®Google Scholar
• Chouaki T, Lavarde V, Lachaud L, Raccurt CP, Hennequin C. Invasive infections due to Trichoderma species: report of 2 cases, findings of in vitro susceptibility testing, and review of the literature. Clin Infect Dis. 2002;35:1360–7.
   PubMed Web of Science ®Google Scholar
• Myoken Y, Sugata T, Fujita Y, Asaoku H, Fujihara M, Mikami Y. Fatal necrotizing stomatitis due to Trichoderma longibrachiatum in a neutropenic patient with malignant lymphoma: a case report. Int J Oral Maxillofac Surg. 2002;31:688–91.
   PubMed Web of Science ®Google Scholar
• De Miguel D, Gómez P, González R, García-Suárez J, Cuadros JA, Bañas MH, et al. Nonfatal pulmonary Trichoderma viride infection in an adult patient with acute myeloid leukemia: report of one case and review of the literature. Diagn Microbiol Infect Dis. 2005;53:33–7.
   PubMed Web of Science ®Google Scholar
• Alanio A, Brethon B, Feuilhade de Chauvin M, de Kerviler E, Leblanc T, Lacroix C, et al. Invasive pulmonary infection due to Trichoderma longibrachiatum mimicking invasive Aspergillosis in a neutropenic patient successfully treated with voriconazole combined with caspofungin. Clin Infect Dis. 2008;46(10):e116–8.
   PubMed Web of Science ®Google Scholar